MARKET

ALKS

ALKS

Alkermes Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.36
+0.51
+1.77%
After Hours: 29.36 0 0.00% 16:05 05/26 EDT
OPEN
28.88
PREV CLOSE
28.85
HIGH
29.54
LOW
28.32
VOLUME
917.28K
TURNOVER
0
52 WEEK HIGH
33.00
52 WEEK LOW
21.24
MARKET CAP
4.80B
P/E (TTM)
-77.1211
1D
5D
1M
3M
1Y
5Y
BRIEF-Alkermes Announces Continued Board Refreshment
reuters.com · 4h ago
Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors
Alkermes plc (Nasdaq: ALKS) today announced a series of actions as part of its ongoing commitment to strong corporate governance and regular board refreshment. The company also filed its preliminary proxy statement with the U.S. Securities and Exchange Com...
PR Newswire · 6h ago
Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL
Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.
Zacks · 10h ago
Esperion (ESPR) Up More Than 12% YTD: What's Driving the Rally?
Esperion's (ESPR) marketed drugs are the key drivers of the stock. Sales of the drugs increase more than 100% during the first quarter. Strong sales growth is expected to continue in 2022 as well as 2023.
Zacks · 13h ago
Reasons to Hold on to Myriad Genetics (MYGN) Stock for Now
Investors are optimistic about Myriad Genetics (MYGN) owing to strong Q1 2022 results and growth in testing volumes.
Zacks · 17h ago
Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease
Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.
Zacks · 1d ago
Here's Why You Must Add Masimo (MASI) Stock to Your Portfolio
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Zacks · 1d ago
Masimo's (MASI) PVi Favored by New Study for Pediatric Patients
Masimo's (MASI) PVi is expected to take better treatment decisions for pediatric patients with signs of obstructive respiratory disease in the EDs.
Zacks · 1d ago
More
No Data
Learn about the latest financial forecast of ALKS. Analyze the recent business situations of Alkermes Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

10.00%Strong Buy
30.00%Buy
50.00%Hold
10.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALKS stock price target is 31.75 with a high estimate of 37.00 and a low estimate of 27.00.
High37.00
Average31.75
Low27.00
Current 29.36
EPS
Actual
Estimate
0.080.150.220.30
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 331
Institutional Holdings: 165.49M
% Owned: 101.26%
Shares Outstanding: 163.43M
TypeInstitutionsShares
Increased
76
10.31M
New
33
1.76M
Decreased
74
6.83M
Sold Out
38
2.09M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Chairman/Chief Executive Officer/Director
Richard Pops
Chief Financial Officer/Senior Vice President
Iain Brown
Chief Operating Officer/Executive Vice President
Blair Jackson
Executive Vice President
Craig Hopkinson
Senior Vice President/Chief Compliance Officer/Secretary
David Gaffin
Senior Vice President/Chief Risk Officer
Michael Landine
Senior Vice President
C.Todd Nichols
Lead Director/Independent Director
David Anstice
Director
Shane Cooke
Independent Director
Emily Alva
Independent Director
David Daglio
Independent Director
Wendy Dixon
Independent Director
Richard Gaynor
Independent Director
Cato Laurencin
Independent Director
Brian Mckeon
Independent Director
Nancy Snyderman
Independent Director
Frank Wilson
Independent Director
Nancy Wysenski
No Data
No Data
About ALKS
Alkermes Public Limited Company is a fully integrated biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The Company's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Webull offers kinds of Alkermes Plc stock information, including NASDAQ:ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.